Research programme: parathyroid hormone analogues - Zelos Therapeutics

Drug Profile

Research programme: parathyroid hormone analogues - Zelos Therapeutics

Alternative Names: ZT 100

Latest Information Update: 14 Oct 2009

Price : $50

At a glance

  • Originator Zelos Therapeutics Inc
  • Class Peptide fragments; Peptide hormones
  • Mechanism of Action Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bone disorders; Haematological disorders
  • Discontinued Osteoporosis

Most Recent Events

  • 23 Jan 2007 Preclinical trials in Osteoporosis in USA (Transdermal)
  • 23 Jan 2007 Preclinical trials in Bone disorders in USA (Parenteral)
  • 09 Aug 2005 Preclinical trials in Haemtological disorders (stem cell transplant) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top